Market Overview

2018 Gene Therapy in Oncology - There is a Significant Opportunity for Developing Combination Regimens - ResearchAndMarkets.com

Share:

The "Gene
Therapy in Oncology"
report has been added to ResearchAndMarkets.com's
offering.

Currently only small size biotech and pharmaceutical companies dominate
the pipeline for cancer gene therapies. With J&J having the exclusive
worldwide rights to develop and commercialize Geron's imetelstat and
AstraZeneca the only large pharmaceutical company with an in-house gene
therapy in late stage clinical development; Merck & Co. and BMS are
evaluating their respective in-house CPI therapies with many of the
Phase II and III candidates in the cancer gene therapy pipeline.

KOLs see a huge potential for cancer gene therapies, particularly in
combination with immune CPIs. To this end, there is a significant
opportunity for developing combination regimens as half of the Phase III
pipeline is evaluated as a monotherapy and only one candidate is
evaluated in combination with a CPI in their pivotal studies.

Scope

  • Overview of Cancer Gene Therapy: What are the gene transfer methods
    and strategies used in oncology.
  • Cancer Gene Therapy in the 8MM: What is the regulatory framework
    concerning development and approval of cancer gene therapies in the
    8MM and what are the currently marketed gene therapies in the oncology
    space in the 8MM.
  • Clinical Development of Gene Therapies in Oncology: What are the late
    stage pipeline cancer gene therapies.
  • Clinical Trial Mapping and Design: How are gene therapies positioned
    in the oncology space: what are the oncology indications they are
    targeting and which other therapeutic agents are they being evaluated
    in combination with.
  • Market Outlook for Cancer Gene Therapies in Oncology: When are cancer
    gene therapies expected to be marketed for various oncology
    indications, what are some of the most promising candidates, and what
    are some challenges that cancer gene therapies are expected to face
    following their launch.
  • Reimbursement of Gene Therapies in Oncology: What are the challenges
    associated with reimbursement of novel cancer therapies and some
    strategies to contain the cost of cancer gene therapies.

Companies Featured

  • Advantage
  • Advaxis Immunotherapies
  • Amgen
  • Ascend Biopharmaceuticals
  • AstraZeneca
  • Bio-Path Holdings
  • Bristol-Myers Squibb
  • Cold Genesys
  • CRISPR Therapeutics
  • Daiichi Sankyo
  • DNAtrix
  • Editas Medicine
  • Geron Corp
  • Idera Pharmaceuticals
  • Intellia Therapeutics
  • Johnson & Johnson
  • Marsala Biotech
  • Merck & Co
  • Mologen AG
  • MTG Biotherapeutics
  • Oncolytics Biotech
  • Oncosec
  • Oncotelic
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • Silenseed
  • Sillajen Biotherapeutics
  • SynerGene Therapeutics
  • Takara Holdings
  • Targovax
  • Tocagen
  • UniQure
  • Vascular Biogenics
  • Ziopharm Oncology

For more information about this report visit https://www.researchandmarkets.com/research/tzbz5k/2018_gene_therapy?w=4

View Comments and Join the Discussion!